Sort
8,912 grants matching “sars cov 2”
Evaluating influenza, SARS-CoV-2, and other respiratory virus vaccine effectiveness in prevention of acute illness in Washington state 2022-2027
$2,000,000Karen J Wernli · Kaiser Foundation Health Plan Of Washington · U01 · FY2022 · IP
SICA Study: Seroepidemiological Insight into COVID-19 transmission in Africa
$2,000,000Rhoel David Ramos Dinglasan · University Of Florida · U01 · FY2021 · GH
Wastewater Detection of COVID-19
$2,000,000Jeff Wenzel · Missouri State Dept/ Health & Senior Srv · U01 · FY2021 · DA
IP21-002, US Enhanced Surveillance Network to Assess Burden, Natural History, and Effectiveness of Vaccines to Prevent Enteric and Respiratory Viruses in Children
$2,000,000Rangaraj Selvarangan · Children'S Mercy Hosp (Kansas City, Mo) · U01 · FY2025 · IP
RADx-UP CDCC
$2,000,000Michael Cohen-Wolkowiez · Duke University · U24 · FY2023 · MD
Prospective Cohort to Assess Novel and Repeated SARS-CoV-2 Infection and COVID-19 Illness within a US State or Region
$2,000,000National Cancer Institute · Y01 · FY2021 · CA
Component A _ Credible Effectiveness Measures of Seasonal Influenza, COVID-19 and Other Respiratory Virus Vaccines against Ambulatory Care for Acute Illness in Texas (and Component D).
$2,000,000Manjusha Gaglani · Baylor Research Institute · U01 · FY2022 · IP
AOU WI Area of Interest 1: Community, Participant and Provider Engagement, Enrollment...
$2,000,000Scott Joseph Hebbring · Marshfield Clinic Research Foundation · OT2 · FY2024 · OD
Michigan-Ford Initiative to Measure Vaccine Effectiveness (MFIVE): Seasonal Influenza, COVID-19 and Respiratory Virus Vaccines
$1,999,909Emily Toth Martin · University Of Michigan At Ann Arbor · U01 · FY2022 · IP
Center for Excellence in Host Pathogen Interactions
$1,998,812David S. Bradley · University Of North Dakota · P20 · FY2024 · GM
Epigenomics and DNA Sequencing
$1,998,360Paul A Wade · National Institute Of Environmental Health Sciences · ZIC · FY2023 · ES
Query Log Analysis for Improving User Access to NCBI Web Services
$1,997,904Zhiyong Lu · National Library Of Medicine · ZIA · FY2021 · LM
Autonomously deploying, co-evolving SARS-CoV-2 antiviral: a new paradigm for pandemic prevention
$1,997,089Robert Rodick · Vxbiosciences, Inc. · R01 · FY2023 · AI
An Open-access 700 MHz NMR Spectrometer for Central New England
$1,996,603Jeffrey C Hoch · University Of Connecticut Sch Of Med/Dnt · S10 · FY2023 · OD
IP21-002 US Enhanced Surveillance Network to Assess Burden, Natural History, and Effectiveness of Vaccines to Prevent Enteric and Respiratory Viruses in Children
$1,996,220Mary A Staat · Cincinnati Childrens Hosp Med Ctr · U01 · FY2025 · IP
SARS-CoV-2 Screening and Diagnostic testing for return to K-12 schools
$1,995,475Kanecia Obie Zimmerman · Duke University · OT2 · FY2022 · HD
Immune Regulation of COVID-19 Infection in Cancer and Autoimmunity
$1,995,375Ignacio E. Sanz · Emory University · U54 · FY2022 · CA
Center for Serological Testing to Improve Outcomes from Pandemic COVID-19 (STOP-COVID)
$1,995,256Eugene M. Oltz · Ohio State University · U54 · FY2022 · CA
Molecular Approaches To Antiviral Development For Viral Hepatitis and Other Viral Diseases
$1,991,797T. Jake Liang · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2022 · DK
COVID-19: Identification and Development of Clinical Candidates to Treat SARS-CoV-2
$1,991,523Donald Lo · National Center For Advancing Translational Sciences · ZIA · FY2020 · TR
Features of Broad T Cell Coronavirus Immunity
$1,987,375Andrew D Luster · Brigham And Women'S Hospital · P01 · FY2023 · AI
Biobehavioral Imaging and Molecular Neuropsychopharmacology of Substance Abuse Mechanisms
$1,981,761Michael Michaelides · National Institute On Drug Abuse · ZIA · FY2022 · DA
Eosinophils and Eosinophil Activation in the Pathogenesis of Human Disease
$1,980,543Amy Klion · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI
Mechanisms and Duration of Immunity to SARS-CoV-2
$1,980,075Scott Dexter Boyd · Stanford University · U54 · FY2022 · CA
NCHS-CDC NHIS Taste & Smell and NHIS Voice, Speech, and Language Questionnaire Supplements
$1,975,000Stephen Blumberg · National Institute On Deafness And Other Communication Disorders · Y01 · FY2022 · DC